VXRT News and Press, Vaxart Inc. From 09/14/20

Recruitment for Phase 1 clinical study expected to start this month Data from ongoing hamster challenge study expected in October SOUTH SAN FRANCISCO, Calif., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral vaccines that are a...

At the beginning of 2020,  Altimmune (NASDAQ: ALT) and  Vaxart (NASDAQ: VXRT) were tiny biotechs with market caps below $30 million. They weren't even big enough to be considered microcap stocks. Most investors had never heard of either company. Fast forward to today. Shares of ...

Which biotech companies will become the superstars of tomorrow and push your portfolio performance into the stratosphere? It's impossible to predict the future of the stock market with perfect precision, but we can identify companies with promise. One method of finding great stocks is to hunt ...

Intra-Cellular Therapies (ITCI  +74%  on positive topline results from its Phase 3 clinical trial. More news on: Astrotech Corporation, Vaxart, Inc., Chembio Diagnostics, Inc., Stocks on the move, , Read more ...

Many COVID-19 vaccine players are in the green premarket in apparent response to a potential safety signal in a Phase 3 study of AstraZeneca's (NYSE: AZN ) AZD1222. AZN is down  2%  on light volume. More news on: AstraZeneca PLC, Sanofi, GlaxoSmithKline plc, Healthcare stocks...

Shares of COVID-19 vaccine developer Vaxart (NASDAQ: VXRT) and coronavirus diagnostic test manufacturers Opko Health (NASDAQ: OPK) and Quidel (NASDAQ: QDEL) plunged more than 35% in August, according to data provided by S&P Global Market Intelligence . Vaxart's shares were down...

There are a number of reasons why you might be interested in the future sales/revenue growth of a company. For instance, in order to perform a discounted cash flow analysis of a stock, it's one of the essential inputs. Or perhaps, you believe that the higher a company's projected sales growth,...

Vaxart (NASDAQ: VXRT ) announces pre-publication of a manuscript titled “Preclinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection.” More news on: Vaxart, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Albireo Pharma (NASDAQ: ALBO ) +82%  as odevixibat successful in late-stage study. More news on: Albireo Pharma, Inc., Nikola Corporation, Luby's, Inc., Stocks on the move, , Read more ...

Triggering mucosal immunity may be crucial for effective protection against SARS-CoV-2 infection and transmission Vaxart’s oral tablet vaccine can overcome major challenges of injectable vaccines SOUTH SAN FRANCISCO, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (...